Drug · CHEMBL1637
GEMCITABINE HYDROCHLORIDE
7 sourcespipelines-2026-09-18-0.3.1
Download JSON
Cite this record
ConductScience Library. GEMCITABINE HYDROCHLORIDE. Drugs and targets, record CHEMBL1637. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1637
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Gemcitabine (as hydrochloride), Gemcitabine hcl, LY-188011 HYDROCHLORIDE, LY188011 HYDROCHLORIDE
- ChEMBL
Targets14
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| POLA1 | DNA polymerase (alpha/delta/epsilon) | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | https://conductscience.org/library/genes/5422 |
| POLA2 | DNA polymerase (alpha/delta/epsilon) | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | https://conductscience.org/library/genes/23649 |
| POLD1 | DNA polymerase (alpha/delta/epsilon) | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | https://conductscience.org/library/genes/5424 |
| POLD2 | DNA polymerase (alpha/delta/epsilon) | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | https://conductscience.org/library/genes/5425 |
| POLD3 | DNA polymerase (alpha/delta/epsilon) | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | https://conductscience.org/library/genes/10714 |
| POLD4 | DNA polymerase (alpha/delta/epsilon) | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | https://conductscience.org/library/genes/57804 |
| POLE | DNA polymerase (alpha/delta/epsilon) | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | https://conductscience.org/library/genes/5426 |
| POLE2 | DNA polymerase (alpha/delta/epsilon) | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | https://conductscience.org/library/genes/5427 |
| POLE3 | DNA polymerase (alpha/delta/epsilon) | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | https://conductscience.org/library/genes/54107 |
| PRIM1 | DNA polymerase (alpha/delta/epsilon) | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | https://conductscience.org/library/genes/5557 |
1 to 10 of 14Source ChEMBL
See all 14 targetsDiseases68
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| non-small cell lung carcinoma | Approval | DailyMed | 48 | 44 | https://conductscience.org/library/drugs?q=MONDO_0005233 |
| malignant pancreatic neoplasm | Phase 3 | ClinicalTrials.gov | 31 | 31 | https://conductscience.org/library/drugs?q=MONDO_0009831 |
| pancreatic neoplasm | Phase 3 | ClinicalTrials.gov | 31 | 31 | https://conductscience.org/library/drugs?q=MONDO_0021040 |
| pancreatic adenocarcinoma | Phase 3 | ClinicalTrials.gov | 30 | 30 | https://conductscience.org/library/drugs?q=MONDO_0006047 |
| exocrine pancreatic carcinoma | Approval | DailyMed | 33 | 29 | https://conductscience.org/library/drugs?q=MONDO_0005192 |
| breast cancer | Approval | DailyMed | 17 | 16 | https://conductscience.org/library/drugs?q=MONDO_0007254 |
| fallopian tube cancer | Phase 3 | ClinicalTrials.gov | 13 | 13 | https://conductscience.org/library/drugs?q=MONDO_0002158 |
| primary peritoneal carcinoma | Phase 3 | ClinicalTrials.gov | 10 | 10 | https://conductscience.org/library/drugs?q=MONDO_0015686 |
| ovarian cancer | Approval | DailyMed | 10 | 9 | https://conductscience.org/library/drugs?q=MONDO_0008170 |
| bladder transitional cell carcinoma | Phase 3 | ClinicalTrials.gov | 9 | 9 | https://conductscience.org/library/drugs?q=MONDO_0005611 |
1 to 10 of 68Source Open Targets
See all 68 diseasesTrials287
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00324805 | Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery | Phase 3 | 1,501 | 2018-02-14 | gemcitabine hydrochloride | Its name | ClinicalTrials.gov |
| NCT00408408 | Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery | Phase 3 | 1,206 | 2017-09-18 | gemcitabine hydrochloride | Its name | ClinicalTrials.gov |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | Phase 3 | 1,052 | 2020-12-14 | gemcitabine hydrochloride | Its name | ClinicalTrials.gov |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Phase 3 | 546 | 2024-10-24 | gemcitabine hydrochloride | Its name | ClinicalTrials.gov |
| NCT00942331 | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | Phase 3 | 506 | 2020-02-17 | gemcitabine hydrochloride | Its name | ClinicalTrials.gov |
| NCT03768414 | Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers | Phase 3 | 452 | 2024-10-22 | gemcitabine hydrochloride | Its name | ClinicalTrials.gov |
| NCT00445601 | S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer | Phase 3 | 406 | 2018-04-24 | gemcitabine hydrochloride | Its name | ClinicalTrials.gov |
| NCT01041781 | Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer | Phase 3 | 313 | 2018-07-23 | gemcitabine hydrochloride | Its name | ClinicalTrials.gov |
| NCT00283244 | Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC | Phase 2 | 147 | 2017-04-24 | gemcitabine hydrochloride | Its name | ClinicalTrials.gov |
| NCT02562716 | S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | Phase 2 | 147 | 2021-07-23 | gemcitabine hydrochloride | Its name | ClinicalTrials.gov |
1 to 10 of 287
See all 287 trialsComparisons in its trials50
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm I (Chemotherapy) vs Arm II (Chemotherapy, Bevacizumab): serious adverse events | 424 of 738 | 563 of 735 | 1,473 | NCT00324805 | Trial comparisons |
| Arm II (GCB) vs Arm I (GCP): deaths from any cause | 207 of 252 | 216 of 254 | 506 | NCT00942331 | Trial comparisons |
| Arm II (GCB) vs Arm I (GCP): Number of Patients Experiencing Grade 3+ Toxicity | 183 of 237 | 163 of 232 | 469 | NCT00942331 | Trial comparisons |
| Arm II (GCB) vs Arm I (GCP): serious adverse events | 95 of 237 | 87 of 232 | 469 | NCT00942331 | Trial comparisons |
| Gem+Cisplatin+Nab-paclitaxel vs Gemcitabine + Cisplatin: deaths from any cause | 237 of 294 | 115 of 147 | 441 | NCT03768414 | Trial comparisons |
| Gem+Cisplatin+Nab-paclitaxel vs Gemcitabine + Cisplatin: serious adverse events | 27 of 287 | 11 of 134 | 421 | NCT03768414 | Trial comparisons |
| Arm I: Gemcitabine vs Arm II: Placebo: deaths from any cause | 17 of 201 | 25 of 205 | 406 | NCT00445601 | Trial comparisons |
| Arm I: Gemcitabine vs Arm II: Placebo: serious adverse events | 7 of 165 | 5 of 174 | 339 | NCT00445601 | Trial comparisons |
| Arm I (Arm A: Celecoxib + Standard Chemotherapy) vs Arm II (Arm B: Placebo + Standard Chemotherapy): deaths from any cause | 15 of 146 | 9 of 148 | 294 | NCT01041781 | Trial comparisons |
| Arm I (Arm A: Celecoxib + Standard Chemotherapy) vs Arm II (Arm B: Placebo + Standard Chemotherapy): serious adverse events | 31 of 146 | 21 of 148 | 294 | NCT01041781 | Trial comparisons |
1 to 10 of 50
See all 50 comparisons in its trialsPapers from its trials111
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1637
GET https://conductscience.org/api/drugs/v1/CHEMBL1637/diseases?page=2